Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

ABSTRACT:

Background

Treatment of pulmonary exacerbations (PEx) in cystic fibrosis (CF) varies widely with no consensus on management practices or best indicators of therapeutic success. To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score and time to next intravenous antibiotic therapy.

Methods

Data were used from a prospective observational study of patients with CF ≥10 years of age enrolled at six sites between 2007 and 2010. All were started on intravenous antibiotics for a clinically diagnosed PEx. Analysis of variance, logistic and Cox regression were used to examine t

SUBMITTER: Heltshe SL 

PROVIDER: S-EPMC4778725 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature